Several Components and Key Tips of a News release

Hong Kong – SEAPRWire categorizes the components of a press release, which can be roughly divided into 6 parts. Below, we’ve broken down each essential piece and how users can implement it expertly into users’ company’s news release format: 1, Headline Just as a newspaper or journal seeks to immediately captivate its audience through a concise, compelling headline, so too should a news release. An effective news release headline is straightforward, engaging, and inclusive of the news release’s objective. 2, Summary The summary should state the key points, touching on who, what, where, when, and why. In doing so, the summary provides the gist of the story users want to share with readers. However, it’s important not to give everything away in the summary. Users still want to entice readers to dive into the body of the press statement. 3, Date and Location Including the date and location of users’ company’s news release is crucial as it gives it a sense of immediacy. Generally, the date and location appear just before the first line of body text, separated by an em dash with spaces. The dateline should capitalize the entire city, abbreviate the state, and give the full date. It should look something like this: New York, NY., January 14, 2022 — First line of body text. 4, Body As the main component of the news release, the body should be concise and engaging. The body expands on the information provided in the summary, fully articulating the release’s key points. Like a resume, the body works best when it packs a short, yet powerfully informative, punch. As such, limit the body of the news release to one page. 5, About Us It provides an overview of the company, specifically highlighting the company’s objectives and operations. 6, Closing When it comes to how to end a news release, the closing isn’t so much a section as it is an indication that the release has reached its conclusion. Crucial Tips for Every News release When crafting users’ company’s news release, you’ll want to make sure that it’s professionally positioned, informative, and concise. As such, we’ve outlined a few news release best practices to ensure that users’ news release is sharp and effective: Be careful not to turn users’ article into clickbait by overinflating the details in users’ headline. Be succinct. As a general rule, headlines composed of fewer than ten words work best. You’ll also want to make sure the summary and body of users’ news release are concise. Be mindful of grammar and syntax. Capitalize the appropriate words and use the appropriate punctuation. Exclamation points should be avoided to evade emotional language or leanings. Use an “inverted pyramid” organization structure in the body of the release. This means arranging the information from most important to least important. Include at least two quotes from key stakeholders. Quotes are important because they provide an easily digestible source of information for reporters and a human touch to the announcement. Break up long chunks of text into smaller paragraphs. In general, paragraphs of no more than 2 to 3 sentences are more digestible to readers. As a distribution newswire, SEAPRWIRE TEAM connect users’ news release to stakeholders within their online newsroom and offer full editorial reviews and targeting and analytics reporting on users’ news release at flat-fee pricing. About SEAPRWire SEAPRWire is the top-up newswire in Southeast Asia. It offers PR distribution service to all Southeast Asia regions, including: Singapore, Vietnam, Thailand, Malaysia, Indonesia, Philippines, Hong Kong and Taiwan. SEAPRWire has a network of media editors, journalists, magazines, newspapers and PR agencies. It also cooperates with top wire services like JCN Newswire, Factiva, Eiko Reuters, Bloomberg, Yahoo, MarketWatch, BusinessInsider. SEAPRWire can distribute press releases in multi-linguages, such as: Traditional Chinese, Simplified Chinese, Thai, Vietnamese, Japanese, Korean, Malay, Indonesian … For quicker communication, please connect on Skype: cs@seaprwire.com Telegram: @seaprwire Media contact Company: SEAPRWire Contact: Tina, Marketing Manager Email: cs@seaprwire.com Website: http://www.seaprwire.com SOURCE: SEAPRWire

Eisai: Application Submitted for Additional Indication of Anti Cancer Agent Lenvima in Combination With Keytruda as a Treatment for Advanced Uterine Body Cancer in Japan

TOKYO, Apr 23, 2021 - (JCN Newswire via SEAPRWire.com) - Eisai Co., Ltd. and MSD K.K., a subsidiary of Merck & Co., Inc., Kenilworth, N.J., U.S.A., (known as MSD outside the United States and Canada) announced today an application submission in Japan for the additional indication of Eisai's in-house discovered and developed multiple receptor tyrosine kinase inhibitor, LENVIMA (generic name: lenvatinib mesylate), in combination with Merck & Co., Inc., Kenilworth, N.J., U.S.A.'s KEYTRUDA (generic name: pembrolizumab) as a treatment for patients with advanced uterine body cancer.This application is based on the results of the pivotal Phase 3 Study 309/KEYNOTE-775 for the treatment of patients with advanced endometrial carcinoma (advanced uterine body cancer in Japan), following at least one prior platinum-based regimen, which were presented at the Society of Gynecologic Oncology (SGO) 2021 Annual Meeting on Women's Cancer in March 2021. In this trial, LENVIMA plus KEYTRUDA demonstrated a statistically significant and clinically meaningful improvement in the primary endpoints of Progression-Free Survival (PFS) and Overall Survival (OS) as well as the secondary endpoint of Objective Response Rate (ORR) versus chemotherapy (treatment of physician's choice of doxorubicin or paclitaxel). The safety profile of LENVIMA plus KEYTRUDA was consistent with previously reported studies.LENVIMA plus KEYTRUDA has received orphan drug designation for a prospective indication for uterine body cancer by the Ministry of Health, Labour and Welfare, Japan (MHLW). Under this system, this application will be subject to priority review.It is estimated that there were more than 417,000 new cases of uterine body cancer diagnosed worldwide and nearly 97,000 deaths from the disease in 2020. In Japan, there were more than 17,000 new cases and more than 3,000 deaths in 2020. Endometrial carcinoma is the most common type of uterine body cancer. It is considered that more than 90% of uterine body cancers occur in the endometrium. Survival is highly dependent on the stage at diagnosis, and with a five-year survival rate of 17% for metastatic disease, the prognosis for these patients is poor.Eisai and MSD have been collaborating through the provision of information on LENVIMA in Japan since October 2018, and will work together to expedite the maximization of contribution by the LENVIMA plus KEYTRUDA combination therapy to patients with cancer. For more information, visit https://www.eisai.com/news/2021/news202131.html. Copyright 2021 JCN Newswire. All rights reserved. (via SEAPRWire)

Ministry of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to Anti-Cancer Agent Lenvima (Lenvatinib) With Prospective Indication for Uterine Body Cancer

TOKYO, Mar 12, 2021 - (JCN Newswire via SEAPRWire.com) - Eisai Co., Ltd. announced today that it has received orphan drug designation for LENVIMA (generic name: lenvatinib mesylate), the orally available multiple receptor kinase inhibitor discovered by Eisai, with a prospective indication for uterine body cancer, by the Ministry of Health, Labour and Welfare (MHLW).In Japan, the estimated number of patients with uterine body cancer is approximately 30,000.1 It is estimated that in 2020, there were more than 17,000 new cases of uterine body cancer and more than 3,000 deaths from the disease.2 It is considered that more than 90% of uterine body cancers occur in the endometrium.3The pivotal Phase 3 Study 309/KEYNOTE-775 evaluated LENVIMA in combination with KEYTRUDA (generic name: pembrolizumab) in patients with advanced endometrial cancer (advanced uterine body cancer in Japan), following at least one prior platinum-based regimen in Japan, the United States, Europe and other countries. In this study, LENVIMA plus KEYTRUDA met its dual primary endpoints, overall survival (OS) and progression-free survival (PFS), as well as its secondary efficacy endpoint of objective response rate (ORR). Currently, Eisai is preparing to submit an application for additional indications based on these results in various countries around the world including Japan.In March 2018, Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A., through an affiliate, entered into a strategic collaboration for the worldwide co-development and co-commercialization of LENVIMA.Eisai positions oncology as a key therapeutic area and is aiming to discover innovative new medicines with the potential to cure cancer. Eisai is committed to expanding the potential clinical benefits of LENVIMA for cancer treatment, as it seeks to contribute addressing the diverse needs of, and increasing the benefits provided to, patients with cancer and their families.Media Inquiries:Public Relations Department,Eisai Co., Ltd.+81-(0)3-3817-5120 Copyright 2021 JCN Newswire. All rights reserved. (via SEAPRWire)

Ethics body aims to create safe space for athletes

All gymnasts are entitled to train without fear of physical or psychological abuse, the Gymnastics Ethics Foundation's (GEF) director Alex McLin reiterated to The Straits Times in a recent interview. The GEF is an independent body set up by the International Gymnastics Federation (FIG) last year in the wake of the USA Gymnastics scandal, which saw its former team doctor Larry Nassar jailed after pleading guilty to sexually abusing athletes under his care. Please subscribe or log in to continue reading the full article. Get unlimited access to all stories at $0.99/month Latest headlines and exclusive stories In-depth analyses and award-winning multimedia content Get access to all with our no-contract promotional package at only $0.99/month for the first 3 months* Subscribe now *Terms and conditions apply.

Weekly tweetbits

SWEET TWEET "Don't let what you can't do stand in the way of what you can do". Cristiano Ronaldo taking a break. CAUGHT ON CAMERA "He's at it again". MMA fighter Hiroaki Suzuki taking on the Body Shot Challenge. Watch: bit.ly/37lp5jr